Statements (67)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:accessories |
occasional shortages reported
|
| gptkbp:activities |
replaces glucocerebrosidase enzyme
|
| gptkbp:affects |
requires ongoing assessment
|
| gptkbp:approves |
requires sterile water for injection
|
| gptkbp:availability |
prescription only
|
| gptkbp:category |
Category C
|
| gptkbp:clinical_trial |
Phase III
long-term treatment studies for efficacy and safety |
| gptkbp:collaborations |
partnerships with academic institutions
|
| gptkbp:community_service |
safety not established in children under 2 years
|
| gptkbp:competitors |
competes with other enzyme therapies
|
| gptkbp:contraindication |
hypersensitivity to imiglucerase
|
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:duration |
every 2 weeks
|
| gptkbp:education |
important for treatment adherence
|
| gptkbp:effective_date |
gptkb:1994
|
| gptkbp:feedback |
generally positive regarding efficacy
|
| gptkbp:formulation |
lyophilized powder
|
| gptkbp:healthcare |
injectable solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cerezyme
|
| gptkbp:indication |
gptkb:Type_1_Gaucher_disease
|
| gptkbp:ingredients |
gptkb:imiglucerase
|
| gptkbp:interacts_with |
may interact with immunosuppressants
|
| gptkbp:is_monitored_by |
regular blood tests required
|
| gptkbp:is_used_for |
gptkb:Gaucher's_disease
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Genzyme
|
| gptkbp:market |
monitoring for adverse effects
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
half-life approximately 2 hours
|
| gptkbp:population |
adults and children
used in diverse populations |
| gptkbp:price |
high
|
| gptkbp:provides_access_to |
available in many countries
|
| gptkbp:provides_information_on |
recommended for Gaucher disease management
|
| gptkbp:receives_funding_from |
funded by pharmaceutical grants
|
| gptkbp:regulatory_compliance |
FDA approved
EMA approved |
| gptkbp:research |
ongoing studies for new formulations
|
| gptkbp:scholarships |
available for financial assistance
|
| gptkbp:side_effect |
gptkb:fandom
fatigue headache nausea abdominal pain pulmonary hypertension thrombocytopenia hepatotoxicity infusion reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:supply_chain |
cold chain logistics required
|
| gptkbp:training |
necessary for administration
|
| gptkbp:treatment |
improves quality of life
reduce symptoms and complications reminders and support systems |
| gptkbp:type_of_insurance |
often covered by insurance plans
|
| gptkbp:bfsParent |
gptkb:Genzyme
gptkb:Sanofi_Genzyme gptkb:Shire_plc gptkb:Shire_Pharmaceuticals gptkb:Genzyme_Corporation |
| gptkbp:bfsLayer |
4
|